The nicotinic modulation of pain

BEKTAŞ TÜRKMEN N., Nemutlu D., Cam M., Okcay Y., Eken H., ARSLAN R.

PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, cilt.33, sa.1, ss.229-239, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 33 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.36721/pjps.2020.33.1.reg.229-239.1
  • Dergi Adı: PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.229-239
  • Anahtar Kelimeler: Analgesia, nicotinic receptors, positive allosteric modulators, ACETYLCHOLINE-RECEPTOR AGONISTS, POSITIVE ALLOSTERIC MODULATION, ALPHA-CONOTOXINS VC1.1, INDUCED ANTINOCICEPTION, INFLAMMATORY PAIN, CALCIUM-CHANNELS, NEUROPATHIC PAIN, SENSORY NEURONS, NERVE LIGATION, RAT MODEL
  • Anadolu Üniversitesi Adresli: Evet

Özet

Pain is a physiological unpleasant sensation that associated with actual or potential tissue damage and affects the major part of human population. Numerous modulatory system control pain through a complex process. The drugs that regulate the modulators involving in this process are currently available; however, the studies to understand the process and develop new agents are still going on. In this review, it is aimed to relay information about how nicotinic receptors contribute the pain modulation. It is obvious that a wide variety of nicotinic receptors is located in both peripheral and central areas. Among these receptors alpha 7, alpha 4 beta 2 and alpha 9 alpha 10 receptor subtypes draw attention in terns of pain modulation. The fact that different receptor subtypes involve in different processes of different pain conditions leads to provide beneficial results from the agonism of alpha 7, alpha 4 beta 2 and antagonism of alpha 9 alpha 10. The major restraint of the usage of nAChR agonists is their adverse effects. However, nowadays, the side effects are reduced by the clinical developments. Additionally, positive allosteric modulators that amplify the effectiveness of nAChR ligands are in demand.